Moreover, CNS disorders are often difficult to treat (Gooch et al., 2017), which is in part because many CNS active drugs are substrates of ABCB1 and ABCG2 at the blood-brain barrier. This evidence concerns the gene ABCB1 and central nervous system disorder.